A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
- Conditions
- Healthy SubjectsPharmacokinetics of ASP015K
- Interventions
- Drug: ASP015KDrug: verapamil
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02111317
- Locations
- 🇺🇸
PAREXEL, Glendale, California, United States
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
- Conditions
- DialysisHealthy SubjectsCytomegalovirus Infection
- Interventions
- Drug: ASP0113Drug: Placebo
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02103426
- Locations
- 🇺🇸
Site US10009, Los Angeles, California, United States
🇺🇸Site US10003, Orlando, Florida, United States
🇺🇸Site US10001, Baltimore, Maryland, United States
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
- Conditions
- Metastatic Urothelial Cancer and Other Malignant Solid Tumors
- Interventions
- Drug: enfortumab vedotin
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT02091999
- Locations
- 🇺🇸
Site US00020, Pittsburgh, Pennsylvania, United States
🇺🇸Site US00021, Las Vegas, Nevada, United States
🇺🇸Site US00013, Philadelphia, Pennsylvania, United States
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
- Conditions
- HER2 AmplifiedHuman Epidermal Growth Factor Receptor 2 (HER2)Advanced Breast Cancer
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02091960
- Locations
- 🇨🇦
Site CA15026, Saskatoon, Saskatchewan, Canada
🇨🇦Site CA15001, Quebec, Canada
🇮🇹Site IT39003, Milan, Italy
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
- Conditions
- Prostate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1533
- Registration Number
- NCT02066961
- Locations
- 🇬🇧
Site, Sunderland, United Kingdom
A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects
- Conditions
- Healthy SubjectsPharmacokinetics of 14C-labeled Isavuconazonium Sulfate
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02059590
- Locations
- 🇺🇸
Covance, Madison, Wisconsin, United States
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02057380
- Locations
- 🇺🇸
Site US10004, La Jolla, California, United States
🇺🇸Site US10006, Tampa, Florida, United States
🇺🇸Site US10002, Baltimore, Maryland, United States
A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate
- Conditions
- Pharmacokinetics of ASP2408Rheumatoid Arthritis
- Interventions
- Drug: ASP2408Drug: Placebo
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02052375
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Metroplex Clinical Research Center, LLC, Dallas, Texas, United States
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT02014558
- Locations
- 🇺🇸
Site US10018, Hershey, Pennsylvania, United States
🇺🇸Site US10015, Chicago, Illinois, United States
🇺🇸Site US10020, Hackensack, New Jersey, United States
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses
- Conditions
- Healthy SubjectsFood Effect of ASP4058Pharmacokinetics of ASP4058
- Interventions
- Drug: ASP4058Drug: Placebo
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT01998646
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸Covance Clinical Research Unit, Inc., Evansville, Indiana, United States